Cancer Treatment – TIL (Tumor-Infiltrating Lymphocytes)

Tumor-Infiltrating Lymphocyte (TIL) therapy is one of the most promising breakthroughs in cancer immunotherapy. This personalized treatment uses a patient’s own immune cells that have naturally entered the tumor—called TILs—and reactivates them in a laboratory before infusing them back to attack the cancer with precision.

At RCERT (Regional Cell Research & Therapy Centre), TIL therapy is part of our advanced cell therapy program, focused on delivering safe, cutting-edge, and personalized cancer treatments in Malaysia and Southeast Asia.

🔬 What Are Tumor-Infiltrating Lymphocytes (TIL)?

TILs are a type of T cells found within the tumor microenvironment. Unlike general immune cells circulating in the bloodstream, TILs have already migrated into the tumor site in an attempt to fight the cancer. This means they are:

• Naturally tumor-specific

• Already “educated” by the immune system to recognize cancer antigens

• Proven to have anti-tumor activity (but often suppressed by the tumor itself)

TIL therapy takes advantage of this natural immune recognition and enhances it outside the body before reintroducing it to the patient in a powerful therapeutic dose.

🧪 How TIL Therapy Works

TIL therapy is a form of adoptive cell transfer (ACT). The step-by-step process includes:

1. Tumor Biopsy or Surgical Removal
   A small portion of the tumor is collected from the patient.

2. TIL Extraction
   Lymphocytes (T cells) present within the tumor tissue are isolated in a laboratory.

3. Expansion & Activation
   The TILs are activated and expanded to billions of cells using interleukin-2 (IL-2) and other growth factors.

4. Lymphodepletion (optional)
   The patient may undergo chemotherapy to suppress existing immune cells, creating space for the infused TILs.

5. TIL Infusion
   Expanded TILs are infused back into the patient through IV.

6. Immune Support
   Low-dose IL-2 may be given post-infusion to support the survival and activity of TILs.

🧠 Why TIL Therapy Is Effective

• Tumor-specific targeting: TILs are already trained to recognize tumor antigens.

• Personalized therapy: Each patient’s TILs are unique to their cancer type.

• Overcomes tumor immune suppression: Lab activation boosts the power of TILs.

• Reduced relapse risk: TILs can form immune memory for long-term protection.

Unlike CAR-T cells, which are engineered for specific antigens, TILs are naturally selected by the body — allowing them to recognize multiple cancer targets, including some unknown or mutated antigens (neoantigens).

✅ Clinical Benefits of TIL Therapy

Studies and clinical trials have shown TIL therapy may:

• Shrink tumors that are resistant to chemotherapy or immunotherapy

• Improve overall survival in patients with late-stage cancers

• Be effective even when PD-1/PD-L1 checkpoint inhibitors fail

• Deliver long-term immune surveillance after treatment

• Cause fewer systemic side effects compared to conventional therapies

🏥 TIL Therapy at RCERT

At RCERT, TIL therapy is being developed as part of our personalized oncology strategy in collaboration with:

• UNIMAS (Universiti Malaysia Sarawak)

• Zhongrong Cell Technology Center, China

Our Cell Processing Laboratory is equipped to isolate, expand, and activate TILs under cGMP standards, ensuring clinical safety and performance.

We are exploring TIL therapy particularly for:

• Nasopharyngeal carcinoma (NPC)

• Lung and colorectal cancer

• Cervical and ovarian cancer

• Melanoma and hepatocellular carcinoma (HCC)

🧬 Ideal Candidates for TIL Therapy

TIL therapy is generally recommended for:

• Patients with solid tumors that are not responsive to standard treatment

• Individuals who have failed chemotherapy or checkpoint inhibitor therapy

• Those with accessible tumors for biopsy or resection

• Patients with metastatic cancer, including melanoma, lung, and cervical cancer

A medical evaluation is required to determine eligibility based on tumor characteristics, immune markers, and general health.

⚖️ TIL Therapy vs. Other Immunotherapies

⚠️ Safety and Side Effects

While generally safe, TIL therapy can involve mild to moderate side effects such as:

• Temporary fever or fatigue

• Low white blood cell counts (if lymphodepletion is used)

• Nausea or chills post-infusion

• Mild skin rash or injection site soreness

RCERT ensures all patients are monitored in a controlled medical setting before, during, and after treatment.

📈 Global Recognition of TIL Therapy

In recent years, TIL therapy has gained momentum in major cancer centers:

• MD Anderson Cancer Center (USA)

• NIH/NCI Clinical Trials

• Iovance Biotherapeutics — pioneering TIL-based drugs

• China, Israel, Europe — accelerating research in cervical, lung, and colorectal cancers

RCERT is proud to be part of this next-generation immunotherapy movement, bringing international standards to the Malaysian and Southeast Asian market.

🌍 The Future of TIL in Malaysia

With Malaysia’s rise in solid tumor incidence and growing interest in personalized medicine, TIL therapy presents an ideal opportunity for:

• Precision oncology centers

• Integrative treatment models

• Long-term survivorship programs

• Medical tourism and regional cell therapy leadership

RCERT is actively building Malaysia’s capacity in TIL R&D, patient therapy, and global partnerships.

📝 Conclusion

Tumor-Infiltrating Lymphocyte (TIL) Therapy is transforming the way cancer is treated — by using the patient’s own immune system to fight back with intelligence and precision.

At RCERT, we believe TIL therapy represents not just treatment, but hope — for patients with advanced, recurrent, or resistant cancers.

📞 Interested in TIL Therapy?
Contact RCERT today to schedule your personalized cancer immunotherapy consultation.